HEPTA Medical Secures $5.7 Million in Series A Funding for Cutting-Edge Non-Surgical Lung Cancer Treatment Technology

HEPTA Medical is thrilled to announce that it has successfully raised $5.7 million in funding to propel its mission of revolutionizing early lung cancer treatment. This innovative company is at the forefront of developing a minimally invasive, non-surgical treatment modality specifically designed to address early-stage lung cancer, which is a critical health challenge as it remains the leading cause of cancer-related deaths globally, with 2.1 million new diagnoses each year. The recent results from major trials, particularly the NLST, underscored the efficacy of lung screening programs in reducing mortality rates, subsequently sparking advancements in technologies that enhance the intersection of navigation, access, diagnosis, and immediate treatment. HEPTA Medical is keen to harness these advancements with its state-of-the-art endoscopically delivered ablation catheter. This pioneering technology utilizes temperature-based feedback and real-time dosing to accurately target and ablate pulmonary nodules, which are precursors to lung cancer, all without the risks associated with traditional surgery or radiation. The funding will be utilized to expedite research and development, enhance clinical trials, and expand awareness of this groundbreaking treatment approach. With this financial boost, HEPTA Medical aims to make significant strides in the fight against lung cancer, providing hope and improved outcomes for patients worldwide. This fundraising milestone is not just a testament to HEPTA Medical's innovative vision, but also reflects the confidence of investors in its potential to transform lung cancer treatment in a meaningful way.